The diagnostic value of a breast cancer diagnosis model based on serum MiRNAs and serum tumor markers.

IF 2.5 3区医学 Q3 ONCOLOGY

World Journal of Surgical Oncology Pub Date : 2025-03-29 DOI:10.1186/s12957-025-03719-z

Xiaohui Li, Feng Wang, Faquan Lin, Binbin Xie, Yi Liu, Yi Xiao, Kai Qin, Weicheng Li, Qiyan Zeng

{"title":"The diagnostic value of a breast cancer diagnosis model based on serum MiRNAs and serum tumor markers.","authors":"Xiaohui Li, Feng Wang, Faquan Lin, Binbin Xie, Yi Liu, Yi Xiao, Kai Qin, Weicheng Li, Qiyan Zeng","doi":"10.1186/s12957-025-03719-z","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer (BCa) is the leading cause of cancer-related death among women worldwide. MicroRNAs (miRNAs) are promising tools for diagnosis and prognosis. This study investigated the role of serum miRNAs and tumor markers (TMs) in the diagnosis of BCa.Methods: Differentially expressed miRNAs were screened from serum samples of BCa patients and healthy individuals via high-throughput sequencing. The expression of hsa-miR-1911-3p, hsa-miR-4694-5p, hsa-miR-548ao-5p, and hsa-miR-4804-3p in 169 BCa patients and 116 healthy controls was detected via qRT-PCR. Serum tumor-associated antigens were detected by chemiluminescence. Logistic regression was subsequently used to develop the miRNA panel I, TM panel II, and (miRNA + TM) panel III models. Receiver operating characteristic (ROC) curve, precision-recall (PR) curve and decision curve analyses (DCA) were performed to assess the accuracy of the three models for BCa diagnosis. Additionally, the relationships between miRNA expression and the clinical characteristics of patients with BCa were assessed.Results: Four serum miRNAs (hsa-miR-1911-3p, hsa-miR-548ao-5p, hsa-miR-4694-5p, and hsa-miR-4804-3p) were newly associated with BCa. The miRNA panel I based on hsa-miR-548ao-5p and hsa-miR-4804-3p showed greater diagnostic effectiveness for BCa than TM panel II based on cancer antigen 125 (CA125) and cancer antigen 153 (CA153), with AUC values of 0.816 and 0.777, respectively. (miRNA + TM) panel III had higher diagnostic effectiveness than miRNA panel I, with an AUC value of 0.870. The expression of miR-548ao-5p and miR-4804-3p is closely related to clinical features, such as human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), HER2-enriched subtype, stage III/IV, and lymph node-transplanted breast cancer.Conclusion: MiR-548ao-5p and miR-4804-3 could serve as potential biomarkers for the diagnosis of BCa.","PeriodicalId":23856,"journal":{"name":"World Journal of Surgical Oncology","volume":"23 1","pages":"109"},"PeriodicalIF":2.5000,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12957-025-03719-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer (BCa) is the leading cause of cancer-related death among women worldwide. MicroRNAs (miRNAs) are promising tools for diagnosis and prognosis. This study investigated the role of serum miRNAs and tumor markers (TMs) in the diagnosis of BCa.

Methods: Differentially expressed miRNAs were screened from serum samples of BCa patients and healthy individuals via high-throughput sequencing. The expression of hsa-miR-1911-3p, hsa-miR-4694-5p, hsa-miR-548ao-5p, and hsa-miR-4804-3p in 169 BCa patients and 116 healthy controls was detected via qRT-PCR. Serum tumor-associated antigens were detected by chemiluminescence. Logistic regression was subsequently used to develop the miRNA panel I, TM panel II, and (miRNA + TM) panel III models. Receiver operating characteristic (ROC) curve, precision-recall (PR) curve and decision curve analyses (DCA) were performed to assess the accuracy of the three models for BCa diagnosis. Additionally, the relationships between miRNA expression and the clinical characteristics of patients with BCa were assessed.

Results: Four serum miRNAs (hsa-miR-1911-3p, hsa-miR-548ao-5p, hsa-miR-4694-5p, and hsa-miR-4804-3p) were newly associated with BCa. The miRNA panel I based on hsa-miR-548ao-5p and hsa-miR-4804-3p showed greater diagnostic effectiveness for BCa than TM panel II based on cancer antigen 125 (CA125) and cancer antigen 153 (CA153), with AUC values of 0.816 and 0.777, respectively. (miRNA + TM) panel III had higher diagnostic effectiveness than miRNA panel I, with an AUC value of 0.870. The expression of miR-548ao-5p and miR-4804-3p is closely related to clinical features, such as human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), progesterone receptor (PR), HER2-enriched subtype, stage III/IV, and lymph node-transplanted breast cancer.

Conclusion: MiR-548ao-5p and miR-4804-3 could serve as potential biomarkers for the diagnosis of BCa.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

World Journal of Surgical Oncology ONCOLOGY-SURGERY

CiteScore

4.70

自引率

15.60%

发文量

362

审稿时长

3 months

期刊介绍： World Journal of Surgical Oncology publishes articles related to surgical oncology and its allied subjects, such as epidemiology, cancer research, biomarkers, prevention, pathology, radiology, cancer treatment, clinical trials, multimodality treatment and molecular biology. Emphasis is placed on original research articles. The journal also publishes significant clinical case reports, as well as balanced and timely reviews on selected topics. Oncology is a multidisciplinary super-speciality of which surgical oncology forms an integral component, especially with solid tumors. Surgical oncologists around the world are involved in research extending from detecting the mechanisms underlying the causation of cancer, to its treatment and prevention. The role of a surgical oncologist extends across the whole continuum of care. With continued developments in diagnosis and treatment, the role of a surgical oncologist is ever-changing. Hence, World Journal of Surgical Oncology aims to keep readers abreast with latest developments that will ultimately influence the work of surgical oncologists.